1415797-56-6

Basic information

• Product Name: 4-(2-(4-nitrophenyl)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)morpholine
• CAS NO: 1415797-56-6
• Molecular Weight: 419.443
• Mol File: 1415797-56-6.mol

Chemical Properties

• CAS DataBase Reference: 4-(2-(4-nitrophenyl)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-(4-nitrophenyl)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)morpholine(1415797-56-6)
• EPA Substance Registry System: 4-(2-(4-nitrophenyl)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)morpholine(1415797-56-6)

Safety Data

• Hazardous Substances Data: 1415797-56-6(Hazardous Substances Data)

Upstream product

• 916420-27-4 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylic acid tert-butyl ester 
• 1722-12-9 2-chloropyrimidine 
• 1207370-33-9 4-(2-(4-nitrophenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)morpholine 
• 1415797-55-5 tert-butyl 4-morpholino-2-(4-nitrophenyl)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate 
• 171364-83-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nitrobenzene 
• 1207370-38-4 tert-butyl 2-chloro-4-morpholino-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate 

Downstream Products

• 1207361-43-0 1-(2-fluoroethyl)-3-(4-(4-morpholino-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea 
• 1207358-77-7 C₂₅H₂₅N₉O 
• 1415797-57-7 6-(benzyloxy)-N-(4-(4-morpholino-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)pyridin-2-amine 
• 1207366-48-0 C₂₆H₂₆N₈O₂ 
• 1207358-78-8 4-(4-morpholino-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)aniline 

Relevant articles and documents

Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349

Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.